| 1 |
33356802 | JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy. | 2021 Jan 2 |
1 |
| 2 |
34361644 | Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway. | 2021 Jul 26 |
1 |
| 3 |
25572535 | Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome. | 2015 Mar |
1 |
| 4 |
26252788 | A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. | 2015 Aug 7 |
1 |
| 5 |
24165976 | A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. | 2014 Apr |
1 |